Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Delaying disease progression in early, non-metastatic CRPC treatment

Bertrand Tombal • 16 Nov 2018
ESMO 2018
Genitourinary Cancer Prostate Cancer Apalutamide Darolutamide Enzalutamide
ARAMIS PROSPER SPARTAN

Trials are underway to investigate the role of nonsteroidal antiandrogens in non-metastatic castration-resistant prostate cancer and Bertrand Tombal, MD, PhD, of Cliniques Saint-Luc University, Brussels, Belgium, summarizes the results from three important clinical trials at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Prof. Tombal presents fascinating data from the PROSPER (NCT02003924), SPARTAN (NCT01946204) and ARAMIS (NCT02200614) trials, exploring the impact of early enzalutamide, apalutamide and darolutamide treatment, respectively, in patients at high risk of developing metastases, and considers the implications associated with a potential approval in this setting.

More from Bertrand Tombal

1:24
PSA limitations in prostate cancer: advancing treatment de-escalation with imaging biomarkers
Bertrand Tombal • 5 Dec 2023
2:54
Time for treatment de-escalation for mHSPC?
Bertrand Tombal • 5 Jan 2024
2:43
Optimizing PSA recurrence treatment
Bertrand Tombal • 5 Dec 2023
2:10
PSA rise factors & significance of doubling time
Bertrand Tombal • 5 Dec 2023

Related Videos

0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
1:08
PSMA imaging pre- and post-177Lu-PSMA-617 treatment in mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals